Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Immunology

• Publication date

  2010-04-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10875-010-9398-1PMID 20424898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• Incidence and prevalence of CIDP and the association of diabetes mellitus

  2009cited by this paper
• Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

  2009cited by this paper
• Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK population

  2009influential reference
• Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

  2008cited by this paper
• Fcγ receptors as regulators of immune responses

  2008cited by this paper
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

  2008cited by this paper
• Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy

  2007cited by this paper
• From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve

  2007cited by this paper
• Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity

  2007cited by this paper
• The impact of glycosylation on the biological function and structure of human immunoglobulins.

  2007cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors

  2006cited by this paper
• Selective dysregulation of the FcγIIB receptor on memory B cells in SLE

  2006cited by this paper
• Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding

  2005cited by this paper
• Chronic inflammatory demyelinating polyneuropathy.

  2005cited by this paper
• The complement system in regulation of adaptive immunity

  2004cited by this paper
• Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease.

  2003cited by this paper
• Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.

  2002cited by this paper
• Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies

  2002cited by this paper
• Welding-related parkinsonism: Clinical features, treatment, and pathophysiology

  2001cited by this paper
• Clinical spectrum of chronic acquired demyelinating polyneuropathies

  2001cited by this paper
• Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy

  2001cited by this paper
• Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

  2001cited by this paper
• Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients

  2000cited by this paper
• Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation.

  2000cited by this paper
• Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII.

  2000cited by this paper
• Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis.

  2000cited by this paper
• Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

  1998cited by this paper
• Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

  1996cited by this paper
• Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein

  1995cited by this paper
• Agalactosyl glycoforms of IgG autoantibodies are pathogenic.

  1994cited by this paper
• Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

  1993cited by this paper
• Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

  1993cited by this paper
• Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura

  1993cited by this paper
• High‐dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy

  1990cited by this paper
• Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice.

  1990cited by this paper
• Glycosylation of IgG, immune complexes and IgG subclasses in the MRL‐lpr/lpr mouse model of rheumatoid arthritis

  1990cited by this paper
• Chronic inflammatory polyradiculoneuropathy.

  1975cited by this paper

• Role of Antibody Glycosylation in Health, Disease, and Therapy.

  2025cites this paper
• Immunoglobulin unresponsive Guillain-Barré syndrome: rinse or repeat? A systematic review

  2025cites this paper
• The function of antibodies

  2024cites this paper
• Recurrent CNTN1 antibody-positive nodopathy: a case report and literature review

  2024cites this paper
• IgG4-Related Peripheral Neuropathy with Unilateral Cervical Nerve Root and Brachial Plexus Swelling: A Case Report

  2022cites this paper
• IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies

  2022cites this paper
• CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review

  2022cites this paper
• Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases

  2021cites this paper
• Nodal and paranodal antibody-associated neuropathies

  2021cites this paper
• Overexpression of FcγRIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus

  2020cites this paper
• Existing and Emerging Approaches to Treating Chronic Inflammatory Demyelinating Polyneuropathy

  2019cites this paper
• Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease.

  2019cites this paper
• Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer

  2019cites this paper
• Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications

  2017cites this paper
• Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.

  2017influential citation
• Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation

  2017cites this paper
• Role of Fcγ Receptor Mediated Inflammation in Immune Neuropathies

  2017cites this paper
• Therapeutic Advances in Neurological Disorders

  2017cites this paper
• Two years’ long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment

  2017cites this paper
• Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP

  2017cites this paper
• Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury.

  2016cites this paper
• Intravenous immunoglobulin in the treatment of neurologic disorders

  2016cites this paper
• Accelerated atherosclerosis in patients with common variable immunodeficiency: Is it overlooked or absent?

  2015cites this paper
• bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody‐mediated immune activation and repression

  2015cites this paper
• Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.

  2015cites this paper
• Immunorégulation de la réaction du greffon contre l'hôte (GvHD) dans un modèle murin xénogénique : le rôle des immunoglobulines intraveineuses (IVIG)

  2015cites this paper
• Role of FcγRIIIA (CD16) in IVIg-Mediated Anti-Inflammatory Function

  2014cites this paper
• Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies.

  2014cites this paper
• New and emerging treatments of Guillain–Barré syndrome

  2014cites this paper
• Regulation and Programming of Antibody Effector Function through IgG Glycosylation

  2014cites this paper
• Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg

  2014cites this paper
• Molecular and Cellular Pathways of Immunoglobulin G Activity In Vivo

  2014cites this paper
• The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease.

  2013cites this paper
• Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy

  2013cites this paper
• Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders.

  2013cites this paper
• Przewlekła zapalna polineuropatia demielinizacyjna

  2013cites this paper
• Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)

  2013cites this paper
• Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

  2013cites this paper
• IVIg‐mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1

  2012cites this paper
• FcγRIIB: a modulator of cell activation and humoral tolerance

  2012cites this paper
• B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo

  2012cites this paper
• Novel roles for the IgG Fc glycan

  2012cites this paper
• Sialylation‐independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin

  2012cites this paper
• Analysis and Functional Consequences of Increased Fab-Sialylation of Intravenous Immunoglobulin (IVIG) after Lectin Fractionation

  2012cites this paper
• Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.

  2012cites this paper
• Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson’s disease

  2012cites this paper
• The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo

  2011cites this paper
• Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.

  2011cites this paper